This study is for adults 18 and older with metastatic pancreatic ductal adenocarcinoma (**mPDAC**), a type of advanced pancreatic cancer. The study will test the safety and effectiveness of a drug called TTX-030, with or without another drug called budigalimab, alongside chemotherapy. Chemotherapy involves two drugs: gemcitabine and nab-paclitaxel, which are standard treatments (**SOC**) for mPDAC. Participants should not have received prior treatment for their metastatic cancer and need to show measurable disease according to special guidelines (**RECIST 1.1**). The study is open-label, meaning participants and researchers know which treatments are being given. Participants need to have a good performance status, meaning they should be able to carry out daily activities with little or no help.

• Participants must be willing to give informed consent and be able to follow the study requirements.
• The study will take place at several locations, so travel may be involved.
• Potential risks include side effects from treatments, such as allergies or reactions to drugs.